Dataset from A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113

The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to
determine the safety profile of orally administered brigatinib, including: the maximum
tolerated dose (MTD), dose limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and
pharmacokinetic (PK) profile. Then, once the RP2D is established, an expansion phase will
assess the preliminary anti-tumor activity of brigatinib, both in non-small cell lung cancer
(NSCLC) with ALK gene rearrangement (including participants with active brain metastases) or
mutated EGFR, and in other cancers with abnormal targets against which brigatinib is active.